Meeting
2021 ASCO Annual Meeting
Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
Authors
Meletios A. Dimopoulos
Therapeutic Clinic, General Hospital of Athens Alexandra, Athens, Greece
Meletios A. Dimopoulos , Fredrik Schjesvold , Vadim Doronin , Olga Vinogradova , HANG QUACH , Xavier Leleu , Gonzalez montes Yolanda , Karthik Ramasamy , Alessandra Pompa , Mark-David Levin , Cindy Lee , Ulf-Henrik Mellqvist , Roland Fenk , Hamdi Sati , Alexander Vorog , Richard J. Labotka , Jichang Du , Mohamed Darif , Shaji Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03170882
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8020)
DOI
10.1200/JCO.2021.39.15_suppl.8020
Abstract #
8020
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu